Equities research analysts forecast that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings per share (EPS) of ($0.17) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Evoke Pharma’s earnings, with estimates ranging from ($0.19) to ($0.14). Evoke Pharma posted earnings per share of ($0.14) in the same quarter last year, which would suggest a negative year over year growth rate of 21.4%. The company is expected to report its next earnings results on Monday, May 21st.

According to Zacks, analysts expect that Evoke Pharma will report full year earnings of $0.10 per share for the current fiscal year, with EPS estimates ranging from ($0.47) to $1.16. For the next year, analysts anticipate that the business will post earnings of $0.51 per share, with EPS estimates ranging from ($0.83) to $1.85. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Evoke Pharma.

How to Become a New Pot Stock Millionaire

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.21.

A number of analysts have issued reports on EVOK shares. HC Wainwright set a $9.00 target price on Evoke Pharma and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Thursday, March 8th. B. Riley reaffirmed a “buy” rating and issued a $5.00 target price (down from $10.00) on shares of Evoke Pharma in a research note on Thursday, March 8th. Finally, ValuEngine downgraded Evoke Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $7.71.

Shares of Evoke Pharma (NASDAQ:EVOK) opened at $2.07 on Tuesday. Evoke Pharma has a 52 week low of $1.85 and a 52 week high of $4.09.

Several large investors have recently modified their holdings of EVOK. Creative Planning acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $226,000. B. Riley Financial Inc. acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $249,000. 683 Capital Management LLC acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $258,000. Deutsche Bank AG acquired a new stake in shares of Evoke Pharma during the 4th quarter worth about $452,000. Finally, Vanguard Group Inc. increased its position in shares of Evoke Pharma by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the last quarter. 18.42% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Zacks: Analysts Anticipate Evoke Pharma Inc (EVOK) Will Post Earnings of -$0.17 Per Share” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/zacks-analysts-anticipate-evoke-pharma-inc-evok-will-post-earnings-of-0-17-per-share/1961179.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.